• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/25/25 6:14:35 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    hsic-20250225
    0001000228 false NASDAQ 0001000228 2025-02-25 2025-02-25
     
     
     
     
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON,
     
    D.C. 20549
    FORM
    8-K
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported):
    February 25, 2025
    Henry Schein, Inc.
    (Exact name of registrant as specified in its charter)
     
    Delaware
    (State or other jurisdiction
    of incorporation)
     
    0-27078
    (Commission
    File Number)
     
    11-3136595
    (IRS Employer
    Identification No.)
     
     
     
     
     
    135 Duryea Road
    ,
    Melville
    ,
    New York
    (Address of principal executive offices)
    11747
    (Zip Code)
    Registrant’s telephone number, including area code: (
    631
    )
    843-5500
    (Former name or former address, if changed since last
     
    report.)
    Check the appropriate box
     
    below if the
     
    Form 8-K filing is intended to simultaneously satisfy
     
    the filing obligation of
     
    the registrant under any
     
    of the following
    provisions:
    ☐
     
    Written communications pursuant
     
    to Rule 425
     
    under the Securities
     
    Act (17 CFR 230.425)
    ☐
     
    Soliciting material pursuant to
     
    Rule 14a-12 under
     
    the Exchange Act (17
     
    CFR 240.14a-12)
    ☐
     
    Pre-commencement communications pursuant to
     
    Rule 14d-2(b) under
     
    the Exchange Act
     
    (17 CFR 240.14d-2(b))
    ☐
     
    Pre-commencement communications pursuant to
     
    Rule 13e-4(c) under the
     
    Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to
     
    Section 12(b) of the
     
    Act:
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, par value $.01 per share
     
    HSIC
     
    The Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth
     
    company as defined in Rule 405 of the Securities Act
     
    of 1933 (§230.405 of this chapter) or Rule
    12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
     
    of this chapter).
    Emerging growth company
     
    ☐
    If an emerging growth company,
     
    indicate by check mark if the registrant has
     
    elected not to use the extended transition period
     
    for complying with any new or revised
    financial accounting standards provided pursuant to Section 13(a) of
     
    the Exchange Act.
     
    ☐
     
    Item 2.02.
     
    Results of Operations and Financial Condition.
    On February 25, 2025, Henry Schein, Inc. issued a press release
     
    reporting the financial results for the three
    months and full year ended December 28, 2024.
     
    The full text of the press release is attached hereto as Exhibit
     
    99.1 and
    is incorporated herein by reference.
    The information in this Item 2.02 and the press release attached as Exhibit
     
    99.1 are considered furnished to the
    Securities and Exchange Commission and are not deemed filed for purposes
     
    of Section 18 of the Securities Exchange
    Act of 1934, as amended.
    Item 9.01.
     
    Financial Statements and Exhibits
    (a)
     
    Not applicable.
    (b)
     
    Not applicable.
    (c)
     
    Not applicable.
    (d)
     
    Exhibit 99.1 – Press Release dated February 25, 2025.
    Exhibit 104 - Cover Page Interactive Data File (embedded within the
     
    Inline XBRL document)
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the
     
    registrant has duly caused this report to
    be signed on its behalf by the undersigned hereunto duly authorized.
    HENRY SCHEIN, INC.
    By:
    /s/ Ronald N. South
    Ronald N. South
    Senior Vice President and
    Chief Financial Officer
    (Authorized Signatory and Principal
    Financial and Accounting Officer)
    February 25, 2025
    EXHIBIT INDEX
    Exhibit No.
    Description
    99.1
    Press Release dated February 25, 2025.
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL
     
    document)
    Get the next $HSIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    11/10/2023$70.00Hold → Buy
    Stifel
    8/8/2022$80.00Sell → Neutral
    UBS
    More analyst ratings

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Henry Schein with a new price target

      Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

      2/14/25 7:05:26 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein upgraded by BofA Securities with a new price target

      BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously

      1/6/25 8:12:21 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Mizuho initiated coverage on Henry Schein with a new price target

      Mizuho initiated coverage of Henry Schein with a rating of Neutral and set a new price target of $75.00

      12/4/24 7:41:29 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Henry Schein Inc.

      SCHEDULE 13D/A - HENRY SCHEIN INC (0001000228) (Subject)

      5/6/25 4:15:28 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Henry Schein Inc.

      10-Q - HENRY SCHEIN INC (0001000228) (Filer)

      5/5/25 1:41:33 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HENRY SCHEIN INC (0001000228) (Filer)

      5/5/25 6:14:20 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Financials

    Live finance-specific insights

    See more
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

      4/8/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

      Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

      2/25/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      11/13/24 3:30:01 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Henry Schein Inc.

      SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

      11/12/24 9:32:27 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      2/14/24 11:18:57 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Henry Schein to Participate in Upcoming Investor Conferences in May

      Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in May: Bank of America Healthcare Conference at the Encore Hotel in Las Vegas on May 14, 2025, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). Stifel Jaws & Paws Conference at Lotte Hotel, New York City, on May 29, 2025, at 12:40 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc

      5/6/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Medical Announces Winner of Its 2025 Rising Star Award

      Fifth Annual Award Spotlights Up-and-Coming Athletic Trainers Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (NASDAQ:HSIC), announced today that Ian Jeffer, MS, ATC, LAT, Head Athletic Trainer at Desert Ridge High School in Mesa, Arizona, is the winner of the fifth annual Henry Schein Medical Athletics and Schools Rising Star Award. The recognition celebrates emerging athletic trainers with up to five years of experience in the Sports Medicine industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250418934421/en/From left to right: Ian Jeffer, Marissa Lucas, and Angel Picart. Mr. Jeffer was recognized f

      4/22/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Lin Max claimed no ownership of stock in the company (SEC Form 3)

      3 - HENRY SCHEIN INC (0001000228) (Issuer)

      5/8/25 4:10:36 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Director Laskawy Philip A sold $184,999 worth of shares (2,604 units at $71.04), decreasing direct ownership by 10% to 24,805 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      3/20/25 4:28:08 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • EVP & Chief Operating Officer Ettinger Michael S gifted 455 shares, decreasing direct ownership by 0.44% to 103,693 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      3/20/25 4:24:09 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Give Kids A Smile Program Celebrates 23rd Year of Providing Free Oral Health Care Services to Underserved Children

      The American Dental Association Foundation's Initiative, with Exclusive National Sponsors Henry Schein and Colgate-Palmolive, Continues to Expand Its Reach, With Nearly 325,500 Children Expected to Receive Care Throughout 2025 The American Dental Association Foundation (ADA Foundation) is celebrating the 23rd year of its Give Kids A Smile® (GKAS) program, which officially launched on Friday, February 7, at the 2025 national kick-off event at Meharry Medical College School of Dentistry. Since its national launch in 2003, GKAS volunteers have provided free oral health education and services to more than 9.5 million underserved children in the U.S. This press release features multimedia. Vi

      2/10/25 6:30:00 AM ET
      $CL
      $HSIC
      Package Goods/Cosmetics
      Consumer Discretionary
      Medical Specialities
      Health Care